# BRAF Inhibitor Encorafenib And Cetuximab Real Life Investigation of Next Generation CRC Treatment

> **NCT04673955** · — · RECRUITING · sponsor: **Pierre Fabre Pharma GmbH** · enrollment: 500 (estimated)

## Conditions studied

- Metastatic Colorectal Carcinoma

## Interventions

- **DRUG:** Encorafenib
- **DRUG:** Cetuximab

## Key facts

- **NCT ID:** NCT04673955
- **Lead sponsor:** Pierre Fabre Pharma GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2020-09-03
- **Primary completion:** 2026-09
- **Final completion:** 2027-01
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2022-09-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04673955

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04673955, "BRAF Inhibitor Encorafenib And Cetuximab Real Life Investigation of Next Generation CRC Treatment". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04673955. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*